Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Randomized, Double-Blinded, Placebo Controlled, Multi-Cohort Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Subjects

Next Previous
Trial Profile

A Phase 1b Randomized, Double-Blinded, Placebo Controlled, Multi-Cohort Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Subjects

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GS 6207 (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide
  • Indications HIV-1 infections
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 26 Nov 2019 Status changed from recruiting to active, no longer recruiting.
    • 08 Nov 2019 According to a Gilead Sciences media release, new data from two phase I studies were presented at the 17th European AIDS Conference (EACS) in Basel, Switzerland
    • 26 Jul 2019 Planned End Date changed from 1 Aug 2020 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top